Drugging WRN in MSI-H Cancers Available to Purchase

Abstract: Since the discovery of WRN as a synthetic lethal target in microsatellite instability–high tumor types, the development space for drugs against this enzyme has burgeoned. At least two candidates have entered clinical trials—Novartis’s HRO761 and VVD-214 (Vividion Therapeutics/Roche). There are practical realities to consider, however, including the fact that this patient population already benefits greatly from immune checkpoint blockade.